Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for nocturnal bruxism
ACTRN12618001430224Phase 2Completed
- Sponsor
- Melbourne Health
- Start
- Feb 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in bruxism, sponsored by Melbourne Health. Started Feb 2016; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
bruxism
Beyond the preview
Go deeper on ACTRN12618001430224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001430224.